LUZZIO, Michael Joseph,PAPILLON, Julien,VISSER, Michael Scott
申请号:
TN2017000032
公开号:
TN2017000032A1
申请日:
2015.08.05
申请国别(地区):
TN
年份:
2018
代理人:
摘要:
PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absosorption, gastrointestinal tolerance and kinase selectivity.